The Centers for Disease Control and Prevention adjusted their guidelines to encourage doctors to stop testing patients for marijuana as it can lead to “stigmatization” and “inappropriate termination of care.” In an attempt to prevent patients from being denied treatment, the Centers for Disease Control and Prevention (CDC) is urging doctors not to test pain patients on opioids for marijuana. Earlier this month, the CDC released an updated set of guidelines for medical professionals who prescribe opioids to patients with chronic pain. Within those guidelines is language encouraging doctors to not test patients for cannabis since a positive test could disqualify them from continued pain management treatment. “Clinicians should not test for substances for which results would not affect patient management or for which implications for patient management are unclear,” reads the new guideline. “For example, experts noted that there might be uncertainty about the clinical implications of a positive urine drug test for tetrahydrocannabinol (THC).” “Clinicians should not dismiss patients from care based on a urine drug test result because this could constitute patient abandonment and could have adverse consequences for patient safety, potentially including the patient obtaining opioids from alternative sources and the clinician missing opportunities to facilitate treatment for substance use disorder,” the guidelines read. The CDC is also concerned that, if those suffering from pain are disqualified from treatment because of a positive marijuana test, they will try to ease their pain with opioids from the black market. Without a medical professional’s guidance, a patient will be more likely to unknowingly abuse opioids, which will significantly increase the risk of becoming physically dependent and overdosing.